Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine

Tobias D. Wheeler, Dexing Zeng, Amit V. Desai, Birce Önal, David E. Reichert, Paul J.A. Kenis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Radiometal-based radiopharmaceuticals, used as imaging and therapeutic agents in nuclear medicine, consist of a radiometal that is bound to a targeting biomolecule (BM) using a bifunctional chelator (BFC). Conventional, macroscale radiolabeling methods use an excess of the BFC-BM conjugate (ligand) to achieve high radiolabeling yields. Subsequently, to achieve maximal specific activity (minimal amount of unlabeled ligand), extensive chromatographic purification is required to remove unlabeled ligand, often resulting in longer synthesis times and loss of imaging sensitivity due to radioactive decay. Here we describe a microreactor that overcomes the above issues through integration of efficient mixing and heating strategies while working with small volumes of concentrated reagents. As a model reaction, we radiolabel 1,4,7,10-tetraazacyclododecane-1,4, 7,10-tetraacetic acid (DOTA) conjugated to the peptide cyclo(Arg-Gly-Asp-DPhe- Lys) with 64Cu2+. We show that the microreactor (made from polydimethylsiloxane and glass) can withstand 260 mCi of activity over 720 hours and retains only minimal amounts of 64Cu2+ (<5%) upon repeated use. A direct comparison between the radiolabeling yields obtained using the microreactor and conventional radiolabeling methods shows that improved mixing and heat transfer in the microreactor leads to higher yields for identical reaction conditions. Most importantly, by using small volumes (∼10 L) of concentrated solutions of reagents (>50 M), yields of over 90% can be achieved in the microreactor when using a 1:1 stoichiometry of radiometal to BFC-BM. These high yields eliminate the need for use of excess amounts of often precious BM and obviate the need for a chromatographic purification process to remove unlabeled ligand. The results reported here demonstrate the potential of microreactor technology to improve the production of patient-tailored doses of radiometal-based radiopharmaceuticals in the clinic.

Original languageEnglish (US)
Pages (from-to)3387-3396
Number of pages10
JournalLab on a Chip
Volume10
Issue number24
DOIs
StatePublished - Dec 21 2010
Externally publishedYes

Fingerprint

Nuclear medicine
Microfluidics
Nuclear Medicine
Biomolecules
Labeling
Chelating Agents
Ligands
Radiopharmaceuticals
Purification
Imaging techniques
Polydimethylsiloxane
Stoichiometry
Heating
Peptides
Glass
Technology
Acids
Therapeutics

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Chemistry(all)
  • Biomedical Engineering

Cite this

Wheeler, T. D., Zeng, D., Desai, A. V., Önal, B., Reichert, D. E., & Kenis, P. J. A. (2010). Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine. Lab on a Chip, 10(24), 3387-3396. https://doi.org/10.1039/c0lc00162g

Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine. / Wheeler, Tobias D.; Zeng, Dexing; Desai, Amit V.; Önal, Birce; Reichert, David E.; Kenis, Paul J.A.

In: Lab on a Chip, Vol. 10, No. 24, 21.12.2010, p. 3387-3396.

Research output: Contribution to journalArticle

Wheeler, TD, Zeng, D, Desai, AV, Önal, B, Reichert, DE & Kenis, PJA 2010, 'Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine', Lab on a Chip, vol. 10, no. 24, pp. 3387-3396. https://doi.org/10.1039/c0lc00162g
Wheeler, Tobias D. ; Zeng, Dexing ; Desai, Amit V. ; Önal, Birce ; Reichert, David E. ; Kenis, Paul J.A. / Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine. In: Lab on a Chip. 2010 ; Vol. 10, No. 24. pp. 3387-3396.
@article{38aa1d3e1f54403f823bcb8a00a49a28,
title = "Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine",
abstract = "Radiometal-based radiopharmaceuticals, used as imaging and therapeutic agents in nuclear medicine, consist of a radiometal that is bound to a targeting biomolecule (BM) using a bifunctional chelator (BFC). Conventional, macroscale radiolabeling methods use an excess of the BFC-BM conjugate (ligand) to achieve high radiolabeling yields. Subsequently, to achieve maximal specific activity (minimal amount of unlabeled ligand), extensive chromatographic purification is required to remove unlabeled ligand, often resulting in longer synthesis times and loss of imaging sensitivity due to radioactive decay. Here we describe a microreactor that overcomes the above issues through integration of efficient mixing and heating strategies while working with small volumes of concentrated reagents. As a model reaction, we radiolabel 1,4,7,10-tetraazacyclododecane-1,4, 7,10-tetraacetic acid (DOTA) conjugated to the peptide cyclo(Arg-Gly-Asp-DPhe- Lys) with 64Cu2+. We show that the microreactor (made from polydimethylsiloxane and glass) can withstand 260 mCi of activity over 720 hours and retains only minimal amounts of 64Cu2+ (<5{\%}) upon repeated use. A direct comparison between the radiolabeling yields obtained using the microreactor and conventional radiolabeling methods shows that improved mixing and heat transfer in the microreactor leads to higher yields for identical reaction conditions. Most importantly, by using small volumes (∼10 L) of concentrated solutions of reagents (>50 M), yields of over 90{\%} can be achieved in the microreactor when using a 1:1 stoichiometry of radiometal to BFC-BM. These high yields eliminate the need for use of excess amounts of often precious BM and obviate the need for a chromatographic purification process to remove unlabeled ligand. The results reported here demonstrate the potential of microreactor technology to improve the production of patient-tailored doses of radiometal-based radiopharmaceuticals in the clinic.",
author = "Wheeler, {Tobias D.} and Dexing Zeng and Desai, {Amit V.} and Birce {\"O}nal and Reichert, {David E.} and Kenis, {Paul J.A.}",
year = "2010",
month = "12",
day = "21",
doi = "10.1039/c0lc00162g",
language = "English (US)",
volume = "10",
pages = "3387--3396",
journal = "Lab on a Chip - Miniaturisation for Chemistry and Biology",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "24",

}

TY - JOUR

T1 - Microfluidic labeling of biomolecules with radiometals for use in nuclear medicine

AU - Wheeler, Tobias D.

AU - Zeng, Dexing

AU - Desai, Amit V.

AU - Önal, Birce

AU - Reichert, David E.

AU - Kenis, Paul J.A.

PY - 2010/12/21

Y1 - 2010/12/21

N2 - Radiometal-based radiopharmaceuticals, used as imaging and therapeutic agents in nuclear medicine, consist of a radiometal that is bound to a targeting biomolecule (BM) using a bifunctional chelator (BFC). Conventional, macroscale radiolabeling methods use an excess of the BFC-BM conjugate (ligand) to achieve high radiolabeling yields. Subsequently, to achieve maximal specific activity (minimal amount of unlabeled ligand), extensive chromatographic purification is required to remove unlabeled ligand, often resulting in longer synthesis times and loss of imaging sensitivity due to radioactive decay. Here we describe a microreactor that overcomes the above issues through integration of efficient mixing and heating strategies while working with small volumes of concentrated reagents. As a model reaction, we radiolabel 1,4,7,10-tetraazacyclododecane-1,4, 7,10-tetraacetic acid (DOTA) conjugated to the peptide cyclo(Arg-Gly-Asp-DPhe- Lys) with 64Cu2+. We show that the microreactor (made from polydimethylsiloxane and glass) can withstand 260 mCi of activity over 720 hours and retains only minimal amounts of 64Cu2+ (<5%) upon repeated use. A direct comparison between the radiolabeling yields obtained using the microreactor and conventional radiolabeling methods shows that improved mixing and heat transfer in the microreactor leads to higher yields for identical reaction conditions. Most importantly, by using small volumes (∼10 L) of concentrated solutions of reagents (>50 M), yields of over 90% can be achieved in the microreactor when using a 1:1 stoichiometry of radiometal to BFC-BM. These high yields eliminate the need for use of excess amounts of often precious BM and obviate the need for a chromatographic purification process to remove unlabeled ligand. The results reported here demonstrate the potential of microreactor technology to improve the production of patient-tailored doses of radiometal-based radiopharmaceuticals in the clinic.

AB - Radiometal-based radiopharmaceuticals, used as imaging and therapeutic agents in nuclear medicine, consist of a radiometal that is bound to a targeting biomolecule (BM) using a bifunctional chelator (BFC). Conventional, macroscale radiolabeling methods use an excess of the BFC-BM conjugate (ligand) to achieve high radiolabeling yields. Subsequently, to achieve maximal specific activity (minimal amount of unlabeled ligand), extensive chromatographic purification is required to remove unlabeled ligand, often resulting in longer synthesis times and loss of imaging sensitivity due to radioactive decay. Here we describe a microreactor that overcomes the above issues through integration of efficient mixing and heating strategies while working with small volumes of concentrated reagents. As a model reaction, we radiolabel 1,4,7,10-tetraazacyclododecane-1,4, 7,10-tetraacetic acid (DOTA) conjugated to the peptide cyclo(Arg-Gly-Asp-DPhe- Lys) with 64Cu2+. We show that the microreactor (made from polydimethylsiloxane and glass) can withstand 260 mCi of activity over 720 hours and retains only minimal amounts of 64Cu2+ (<5%) upon repeated use. A direct comparison between the radiolabeling yields obtained using the microreactor and conventional radiolabeling methods shows that improved mixing and heat transfer in the microreactor leads to higher yields for identical reaction conditions. Most importantly, by using small volumes (∼10 L) of concentrated solutions of reagents (>50 M), yields of over 90% can be achieved in the microreactor when using a 1:1 stoichiometry of radiometal to BFC-BM. These high yields eliminate the need for use of excess amounts of often precious BM and obviate the need for a chromatographic purification process to remove unlabeled ligand. The results reported here demonstrate the potential of microreactor technology to improve the production of patient-tailored doses of radiometal-based radiopharmaceuticals in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=78649519916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649519916&partnerID=8YFLogxK

U2 - 10.1039/c0lc00162g

DO - 10.1039/c0lc00162g

M3 - Article

C2 - 20941431

AN - SCOPUS:78649519916

VL - 10

SP - 3387

EP - 3396

JO - Lab on a Chip - Miniaturisation for Chemistry and Biology

JF - Lab on a Chip - Miniaturisation for Chemistry and Biology

SN - 1473-0197

IS - 24

ER -